Replies to post #95287 on Titan Medical Inc (TMDIF)

[pmontx16]

777 - OK - but why come up with your $1 price targets - a bit strange to read that over and over again.
To go along with management misses (so to speak), probably, more importantly, take a look at the robot capabilities before and after!
I'm a novice but it's night and day from only a few years back.
Financing has been a debacle - Aspire is a positive - read facts from BigT/Moose etc.
I do agree MC can do a better job communicating with costs, timelines, new goals, new product developments, happenings at the 3 world sites, Stuff like that, but I also realize that companies do not put out releases all that often - especially R&D.
Hope you cheer-lead soon enough. N

[QuidWilson]

I'd argue the primary fiduciary obligation of an R&D company is to deliver shareholder value through commercializing a saleable asset. Different than a cash flowing company. Get to market vs grow market share. That said, it's better to deliver a product to the market with a higher chance of success delayed than to put out a product with less chance of success but on time. Based on the wells fargo presentation it seems the reasons for this delay will increase the probability of regulatory clearance and thus well worth it. I'd argue the diligence in delivering the best possible product to market is the greater act of fiduciary responsibility in this instance.

I understand the frustration...more of the same and all that. I remain optimistic.